8-K
filed May 27, 2026, 4:05 PM ET
ticker APVO
CIK 0001671584
other material
confidence high
sentiment positive
materiality 0.75
Aptevo (APVO) partners with Niowave for radiopharma development; Niowave takes 7.9% equity stake
Aptevo Therapeutics Inc.
- 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs using Aptevo's multispecific platforms and Niowave's radioisotopes.
- Niowave made initial $500K equity investment for 7.9% stake; potential up to 19.99% through warrant exercises at $8.00/share.
- First program targets Nectin-4 with Actinium-225; proof-of-concept study to begin.
- Deal marks Aptevo's expansion into radiopharmaceuticals; Niowave's first therapeutic development investment.
- Niowave to supply radioisotopes if it opts out of collaboration; Aptevo retains development rights.
Key facts
Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.95
Aptevo Therapeutics Inc. issued warrants to purchase 53,201 shares of common stock of warrant to Niowave, Inc. for combined purchase price of $5.075 per share for an aggregate purchase price of approximately $500,000.
- Security
- warrant
- Shares
- warrants to purchase 53,201 shares of common stock
- Purchaser
- Niowave, Inc.
- Consideration
- combined purchase price of $5.075 per share for an aggregate purchase price of approximately $500,000
Exact text from the filing
the Company agreed to initially issue and sell 98,522 of its shares of its common stock, par value $0.001 per share (the “Common Stock”) and accompanying warrants to purchase 53,201 shares of its common stock to Niowave in a private placement at a combined purchase price of $5.075 per share for an aggregate purchase price of approximately $500,000 (the “Initial Niowave Private Placement”).
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.95
Aptevo Therapeutics Inc. issued 98,522 shares of common stock of common stock to Niowave, Inc. for combined purchase price of $5.075 per share for an aggregate purchase price of approximately $500,000.
- Security
- common stock
- Shares
- 98,522 shares of common stock
- Purchaser
- Niowave, Inc.
- Consideration
- combined purchase price of $5.075 per share for an aggregate purchase price of approximately $500,000
Exact text from the filing
the Company agreed to initially issue and sell 98,522 of its shares of its common stock, par value $0.001 per share (the “Common Stock”) and accompanying warrants to purchase 53,201 shares of its common stock to Niowave in a private placement at a combined purchase price of $5.075 per share for an aggregate purchase price of approximately $500,000 (the “Initial Niowave Private Placement”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Aptevo Therapeutics Inc. entered into Collaboration Agreement with Niowave, Inc. (effective 2026-05-25).
- Action
- entry
- Agreement
- collaboration
- Counterparty
- Niowave, Inc.
- Effective
- 2026-05-25
Exact text from the filing
On May 25, 2026, Aptevo Research and Development LLC (“Aptevo Research”), a subsidiary of Aptevo Therapeutics Inc. (the “Company”), and Niowave, Inc. (“Niowave”) entered into a collaboration agreement (the “Collaboration Agreement”) to collaborate on the development of a potential human therapeutic product incorporating Aptevo’s proprietary molecules (including APVO455) and Niowave’s proprietary radioisotopes (including Actinium-225).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Aptevo Therapeutics Inc. entered into Stock Purchase Agreement with Niowave, Inc. valued at approximately $500,000 (effective 2026-05-25).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Niowave, Inc.
- Value
- approximately $500,000
- Effective
- 2026-05-25
Exact text from the filing
on May 25, 2026, the Company entered into a stock purchase agreement with Niowave (the “Stock Purchase Agreement”) pursuant to which the Company agreed to initially issue and sell 98,522 of its shares of its common stock, par value $0.001 per share (the “Common Stock”) and accompanying warrants to purchase 53,201 shares of its common stock to Niowave in a private placement at a combined purchase price of $5.075 per share for an aggregate purchase price of approximately $500,000 (the “Initial Niowave Private Placement”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Aptevo Therapeutics Inc. entered into Investor Rights Agreement with Niowave, Inc. (effective 2026-05-25).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Niowave, Inc.
- Effective
- 2026-05-25
Exact text from the filing
Pursuant to the terms of an investor rights agreement (the “Investor Rights Agreement”) also entered into on May 25, 2026 between Niowave and the Company at the closing of the Initial Niowave Private Placement, Niowave agreed to certain transfer restrictions.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Aptevo Therapeutics Inc. entered into Supply Agreement with Niowave, Inc. (effective 2026-05-25).
- Action
- entry
- Agreement
- supply
- Counterparty
- Niowave, Inc.
- Effective
- 2026-05-25
Exact text from the filing
In connection with the execution of the Collaboration Agreement, the parties concurrently entered into a supply agreement providing for Niowave to supply proprietary radioisotopes (including Actinium-225) to Aptevo to the extent that Niowave elects not to continue with the development program contemplated by the Collaboration Agreement at certain opt-out windows set forth therein, after any such opt-out (the “Supply Agreement”).
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.